This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/bindingdb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/kegg-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/pubchem-compound/
n27http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/iuphar/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n32http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/chemspider/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00708/identifier/chebi/
n29http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00708
rdf:type
n3:Drug
n3:description
An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]
n3:dosage
n20:271B4A74-363D-11E5-9242-09173F13E4C5 n20:271B4A72-363D-11E5-9242-09173F13E4C5 n20:271B4A73-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
265 minutes
n3:indication
Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
n3:manufacturer
n4:271B4A6D-363D-11E5-9242-09173F13E4C5 n4:271B4A6E-363D-11E5-9242-09173F13E4C5 n4:271B4A6B-363D-11E5-9242-09173F13E4C5 n4:271B4A6C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00708 n27:DB00708
dcterms:title
Sufentanil
adms:identifier
n6:46504737 n7:PA451527 n8:41693 n9:D05938 n10:11098-050-01 n18:3534 n19:C08022 n21:3534 n22:38043 n23:DB00708 n25:50012490 n26:9316 n28:Sufentanil
n3:mechanismOfAction
Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
n3:packager
n4:271B4A67-363D-11E5-9242-09173F13E4C5 n4:271B4A68-363D-11E5-9242-09173F13E4C5 n4:271B4A65-363D-11E5-9242-09173F13E4C5 n4:271B4A66-363D-11E5-9242-09173F13E4C5 n4:271B4A69-363D-11E5-9242-09173F13E4C5 n4:271B4A6A-363D-11E5-9242-09173F13E4C5
n3:synonym
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide Sufentanilo Sufentanil Sufentanyl N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide Sufentanilum
n3:toxicity
LD<sub>50</sub>: 18.7 mg/kg (IV in mice)
n14:hasAHFSCode
n15:28-08-08
n3:salt
n3:synthesisReference
Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.
n12:hasConcept
n13:M0026423
foaf:page
n32:sufentanil.html
n3:IUPAC-Name
n11:271B4A79-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B4A7F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B4A7E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B4A7B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B4A7C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B4A7D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B4A8E-363D-11E5-9242-09173F13E4C5 n11:271B4A77-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B4A90-363D-11E5-9242-09173F13E4C5 n11:271B4A78-363D-11E5-9242-09173F13E4C5 n11:271B4A75-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B4A91-363D-11E5-9242-09173F13E4C5 n11:271B4A76-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n29:N01AH03
n3:H-Bond-Acceptor-Count
n11:271B4A85-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B4A86-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B4A80-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B4A81-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B4A83-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B4A82-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B4A84-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56030-54-7
n3:category
n3:containedIn
n24:271B4A70-363D-11E5-9242-09173F13E4C5 n24:271B4A71-363D-11E5-9242-09173F13E4C5 n24:271B4A6F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B4A8A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B4A8C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B4A8D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B4A8F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B4A89-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B4A88-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B4A8B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B4A7A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B4A87-363D-11E5-9242-09173F13E4C5